相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
Helena M. Ditzel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
Comparison of F-18-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study
Lino M. Sawicki et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors
Kobe Dewilde et al.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2018)
The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma
Priya Singh et al.
HISTOPATHOLOGY (2018)
Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on&IT tp53 &ITsequencing results: implications for biology, classification, and staging
Naveena Singh et al.
MODERN PATHOLOGY (2018)
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T. King et al.
QUALITY OF LIFE RESEARCH (2018)
HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
C. Fotopoulou et al.
ANNALS OF ONCOLOGY (2018)
Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA
Lydia Giannopoulou et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2018)
Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
Roberto Tozzi et al.
GYNECOLOGIC ONCOLOGY (2018)
Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type
Sebastien Gouy et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Trial of Optimal Personalised Care After Treatment-Gynaecological Cancer (TOPCAT-G) A Randomized Feasibility Trial
Val Morrison et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols The SPIRIT-PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
W. J. van Driel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic indicators in ovarian serous borderline tumours
Anais Malpica et al.
PATHOLOGY (2018)
Endometriosis-associated ovarian neoplasia
Xavier Matias-Guiu et al.
PATHOLOGY (2018)
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
Robert L. Coleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17
Sandro Pignata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
933OCarboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)
J Pfisterer et al.
ANNALS OF ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria
Steffen Hauptmann et al.
VIRCHOWS ARCHIV (2017)
Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer
Katrijn Michielsen et al.
EUROPEAN JOURNAL OF CANCER (2017)
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial
Roman Rouzier et al.
EUROPEAN JOURNAL OF CANCER (2017)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer
Florence Joly et al.
EUROPEAN JOURNAL OF CANCER (2017)
British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice
Christina Fotopoulou et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2017)
The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review
Giuseppe Scaletta et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience
Heather J. Dalton et al.
GYNECOLOGIC ONCOLOGY (2017)
FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2017)
Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis
Aoshuang Cheng et al.
GYNECOLOGIC ONCOLOGY (2017)
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Amanda N. Fader et al.
GYNECOLOGIC ONCOLOGY (2017)
An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations
Ritu Salani et al.
GYNECOLOGIC ONCOLOGY (2017)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
High-grade serous carcinoma of tubo-ovarian origin: recent developments
Naveena Singh et al.
HISTOPATHOLOGY (2017)
Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al
Philipp Harter et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma
Edwina Coghlan et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
Denis Querleu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Ovarian Cancer Follow-up A Preliminary Comparison of 2 Approaches
Anne Lanceley et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians
W. Glenn McCluggage et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2017)
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial
Ethan Basch et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
David M. Gershenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
Jung-Yun Lee et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman et al.
LANCET ONCOLOGY (2017)
Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer
Allison Gockley et al.
OBSTETRICS AND GYNECOLOGY (2017)
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
Felicia T. Roncolato et al.
ONCOLOGIST (2017)
High grade serous ovarian carcinomas originate in the fallopian tube
S. Intidhar Labidi-Galy et al.
NATURE COMMUNICATIONS (2017)
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
Saeed Rafii et al.
ONCOTARGET (2017)
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
Josephine B. Walton et al.
SCIENTIFIC REPORTS (2017)
Comment on: Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
Thales Paulo Batista
ANNALS OF SURGICAL ONCOLOGY (2017)
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013
A. Oseledchyk et al.
ANNALS OF ONCOLOGY (2017)
Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer
Myong Cheol Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL)
Yolanda Garcia Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Andreas Du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules
Jacques S. Abramowicz et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2017)
Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types
Sebastien Gouy et al.
GYNECOLOGIC ONCOLOGY REPORTS (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
Lucas Minig et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Novel imaging techniques in gynaecological cancer
Vincent Vandecaveye et al.
CURRENT OPINION IN ONCOLOGY (2017)
Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas A Population-based Clinicopathologic Study of 942 Cases
Russell Vang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review
F. Chen et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2017)
Early palliative care for adults with advanced cancer
Markus W. Haun et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study
K. S. Tewari et al.
ANNALS OF ONCOLOGY (2016)
New Pointers for Surgical Staging of Borderline Ovarian Tumors
Sofiane Bendifallah et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?
Luis Chiva et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group
Dirk Timmerman et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2016)
Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy
Eun Ji Han et al.
ANNALS OF NUCLEAR MEDICINE (2016)
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
K. Lindemann et al.
ANNALS OF ONCOLOGY (2016)
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
E. Bentivegna et al.
ANNALS OF ONCOLOGY (2016)
Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned
M. Friedlander et al.
ANNALS OF ONCOLOGY (2016)
Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities
Christina Fotopoulou et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2016)
Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study
Katrijn L. M. Michielsen et al.
BRITISH JOURNAL OF RADIOLOGY (2016)
Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients
Bradley J. Monk et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study
J. Walker et al.
GYNECOLOGIC ONCOLOGY (2016)
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Jacek P. Grabowski et al.
GYNECOLOGIC ONCOLOGY (2016)
Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide
Naveena Singh et al.
GYNECOLOGIC ONCOLOGY (2016)
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2016)
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek et al.
GYNECOLOGIC ONCOLOGY (2016)
Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT)
Nikoline Marie Schou Karlsen et al.
GYNECOLOGIC ONCOLOGY (2016)
Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer A Systematic Literature Review
Alexander Hotouras et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma
Peter G. Rose et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer Updated Guidelines From the European Group on Tumor Markers
Gyorgy Soletormos et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery
Denis Querleu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma
Ignace B. Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
J. K. Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer
Sudeshna Chatterjee et al.
OBSTETRICS AND GYNECOLOGY (2016)
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube
Mark A. Eckert et al.
CANCER DISCOVERY (2016)
Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective
Neil Lineberry et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective
Neil Lineberry et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Kenneth Jaaback et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer
Sarah E. Cousins et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Incidental Serous Tubal Intraepithelial Carcinoma and Early Invasive Serous Carcinoma in the Nonprophylactic Setting Analysis of a Case Series
Jane C. Morrison et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases Further Evidence for the Tubal Origin of High-grade Serous Carcinomas
C. Blake Gilks et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
Ovarian, fallopian tube and peritoneal cancer staging: Rationale and explanation of new FIGO staging 2013
Jaime Prat
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2015)
18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
J. J. You et al.
BRITISH JOURNAL OF CANCER (2015)
Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors
Ines Vasconcelos et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2015)
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients
Enrica Bentivegna et al.
FERTILITY AND STERILITY (2015)
The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer
Erin K. Crane et al.
GYNECOLOGIC ONCOLOGY (2015)
A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
Luis M. Chiva et al.
GYNECOLOGIC ONCOLOGY (2015)
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group
Ignace Vergote et al.
GYNECOLOGIC ONCOLOGY (2015)
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Carol Aghajanian et al.
GYNECOLOGIC ONCOLOGY (2015)
Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum
Naveena Singh et al.
HISTOPATHOLOGY (2015)
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Boehm et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial
Rosalind A. Eeles et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
Andres M. Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Devansu Tewari et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Surveillance and Care of the Gynecologic Cancer Survivor
Stephanie S. Faubion et al.
JOURNAL OF WOMENS HEALTH (2015)
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe et al.
LANCET (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
W. Glenn McCluggage et al.
MODERN PATHOLOGY (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
AMeta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants
Ines Vasconcelos et al.
ONCOLOGIST (2015)
The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters
Naveena Singh et al.
PATHOLOGY (2015)
General practitioners' attitudes toward follow-up after cancer treatment: A cross-sectional questionnaire study
Heidi Lidal Fidjeland et al.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE (2015)
Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer
Xingang Peng et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2015)
Ultrasound in Gynecological Cancer: Is It Time for Re-evaluation of Its Uses?
Daniela Fischerova et al.
CURRENT ONCOLOGY REPORTS (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Impact of adjuvant chemotherapy for stage I ovarian carcinoma with intraoperative tumor capsule rupture
Dai Shimizu et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2015)
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
Theresa A. Lawrie et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Early Detection of High-grade Tubal Serous Carcinoma in Women at Low Risk for Hereditary Breast and Ovarian Cancer Syndrome by Systematic Examination of Fallopian Tubes Incidentally Removed During Benign Surgery
Joseph T. Rabban et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary
C. Uzan et al.
ANNALS OF ONCOLOGY (2014)
Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments
C. Uzan et al.
ANNALS OF ONCOLOGY (2014)
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
F. Trillsch et al.
ANNALS OF ONCOLOGY (2014)
Optimal treatment of early-stage ovarian cancer
F. Collinson et al.
ANNALS OF ONCOLOGY (2014)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
Alison Backen et al.
CLINICAL CANCER RESEARCH (2014)
Bowel obstruction in recurrent gynecologic malignancies: Defining who will benefit from surgical intervention
T. Perri et al.
EJSO (2014)
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer
M. E. L. van der Burg et al.
EUROPEAN JOURNAL OF CANCER (2014)
Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants
Alexandra Leary et al.
GYNECOLOGIC ONCOLOGY (2014)
The role of palliative colorectal stents in gynaecologic malignancy
Leah Jutzi et al.
GYNECOLOGIC ONCOLOGY (2014)
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age
Hiroaki Kajiyama et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer
Rachel N. Grisham et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Low-Grade Serous Tumors of Ovary
Debra A. Bell
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2014)
Primary Ovarian Mucinous Adenocarcinoma of Intestinal Type
Surapan Khunamornpong et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2014)
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Jaime Prat
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2014)
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
Martin R. Stockler et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2014)
Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment
Tilean Clarke et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis
Hyun Jong Park et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2013)
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series
R. Fruscio et al.
ANNALS OF ONCOLOGY (2013)
Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation
Christina Fotopoulou et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
Fiona Collinson et al.
CLINICAL CANCER RESEARCH (2013)
Predictive Biomarkers for Bevacizumab: Are We There Yet?
Dipen Maru et al.
CLINICAL CANCER RESEARCH (2013)
Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials
S. Mahner et al.
EUROPEAN JOURNAL OF CANCER (2013)
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group
Andreas du Bois et al.
EUROPEAN JOURNAL OF CANCER (2013)
Primary invasive mucinous ovarian carcinoma of the intestinal type: Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases
K. Muyldermans et al.
EUROPEAN JOURNAL OF CANCER (2013)
Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab
L. Randall et al.
GYNECOLOGIC ONCOLOGY (2013)
Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?
Ignace Vergote et al.
GYNECOLOGIC ONCOLOGY (2013)
Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options
Emile Darai et al.
HUMAN REPRODUCTION UPDATE (2013)
Salvage Surgery Due To Bowel Obstruction in Advanced or Relapsed Ovarian Cancer Resulting in Short Bowel Syndrome and Long-Life Total Parenteral Nutrition Surgical and Clinical Outcome
Christina Fotopoulou et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer
Xiaoxiang Chen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
Ali Bashashati et al.
JOURNAL OF PATHOLOGY (2013)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
John Farley et al.
LANCET ONCOLOGY (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
Survival in Women With Grade 1 Serous Ovarian Carcinoma
Amanda Nickles Fader et al.
OBSTETRICS AND GYNECOLOGY (2013)
Behavior of Serous Borderline Ovarian Tumors With and Without Micropapillary Patterns: Results of a French Multicenter Study
R. Fauvet et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome
Nour Sneige et al.
CANCER CYTOPATHOLOGY (2012)
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study
Jennifer M. Rubatt et al.
GYNECOLOGIC ONCOLOGY (2012)
BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer
Rebecca Byler Dann et al.
GYNECOLOGIC ONCOLOGY (2012)
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2012)
Impact of Routine Follow-Up Examinations on Life Expectancy in Ovarian Cancer Patients A Simulation Study
Sandra M. E. Geurts et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Adjuvant Chemotherapy for Stage I Clear Cell Carcinoma of the Ovary An Analysis of Fully Staged Patients
Toshio Takada et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Adjuvant Chemotherapy for Stage I Ovarian Clear Cell Carcinoma Is it Necessary for Stage IA?
Mika Mizuno et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions
Elisabetta Kuhn et al.
JOURNAL OF PATHOLOGY (2012)
Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence
Philippe Morice et al.
LANCET ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Low-grade serous primary peritoneal carcinoma
Kathleen M. Schmeler et al.
GYNECOLOGIC ONCOLOGY (2011)
A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study
Robert S. Mannel et al.
GYNECOLOGIC ONCOLOGY (2011)
Accuracy of frozen section diagnosis of ovarian borderline tumor
K. K. Shih et al.
GYNECOLOGIC ONCOLOGY (2011)
Micropapillary pattern in serous borderline ovarian tumors: Does it matter?
Jeong-Yeol Park et al.
GYNECOLOGIC ONCOLOGY (2011)
Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical staging
Cecelia A. Powless et al.
GYNECOLOGIC ONCOLOGY (2011)
No Supportive Evidence for Clinical Benefit of Routine Follow-Up in Ovarian Cancer A Dutch Multicenter Study
Sandra M. E. Geurts et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Considering Early Detection of Relapsed Ovarian Cancer A Review of the Literature
Sandra M. E. Geurts et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Fertility-Sparing Surgery for Borderline Ovarian Tumors Oncologic Safety and Reproductive Outcomes
Taejong Song et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Surgical and Medical Treatment of Clear Cell Ovarian Cancer Results From the Multicenter Italian Trials in Ovarian Cancer (MITO) 9 Retrospective Study
Francescapaola Magazzino et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Clinical Trials in Recurrent Ovarian Cancer
Michael Friedlander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference
Gavin C. E. Stuart et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
Tamar Safra et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary
C. Uzan et al.
ANNALS OF ONCOLOGY (2010)
Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer
Jonathan A. Ledermann et al.
CLINICAL CANCER RESEARCH (2010)
Understanding the problem of inadequately staging early ovarian cancer
P. J. Timmers et al.
EUROPEAN JOURNAL OF CANCER (2010)
Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary
Aminata Kane et al.
FERTILITY AND STERILITY (2010)
The role of restaging borderline ovarian tumors: Single institution experience and review of the literature
Ignacio Zapardiel et al.
GYNECOLOGIC ONCOLOGY (2010)
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2010)
Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up
Stefano Palomba et al.
HUMAN REPRODUCTION (2010)
Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer That Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?
Jamie N. Bakkum-Gamez et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer
Helen J. Mackay et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases
Ali Dastranj Tabrizi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2010)
Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection
Toyomi Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized Trial
Baptist Trimbos et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Less Impact of Adjuvant Chemotherapy for Stage I Clear Cell Carcinoma of the Ovary A Retrospective Japan Clear Cell Carcinoma Study
Masashi Takano et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Palliative surgery versus medical management for bowel obstruction in ovarian cancer
Ali Kucukmetin et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy
Jean-Luc Brun et al.
BMC CANCER (2009)
CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study
Chunqiao Tian et al.
CANCER (2009)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis
Ping Gu et al.
EUROPEAN JOURNAL OF RADIOLOGY (2009)
Prognostic Factors in Patients with Ovarian Serous Low Malignant Potential (Borderline) Tumors with Peritoneal Implants
Aminata Kane et al.
ONCOLOGIST (2009)
Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival
J. D. Wright et al.
BRITISH JOURNAL OF CANCER (2008)
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy
Nilofer S. Azad et al.
CANCER (2008)
Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography - A prospective study
S. Risum et al.
GYNECOLOGIC ONCOLOGY (2008)
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Kathleen M. Schmeler et al.
GYNECOLOGIC ONCOLOGY (2008)
Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients
John F. Smyth et al.
CLINICAL CANCER RESEARCH (2007)
Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
Giovanni D. Aletti et al.
GYNECOLOGIC ONCOLOGY (2007)
Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Philipp Harter et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent
Elvio G. Silva et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Jeffrey Bell et al.
GYNECOLOGIC ONCOLOGY (2006)
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Torbjorn Paulsen et al.
GYNECOLOGIC ONCOLOGY (2006)
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study
Anna Fagotti et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer
Sokbom Kang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2006)
The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma
DD Rosa et al.
EJSO (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion
S Chen et al.
MODERN PATHOLOGY (2005)
Ovarian serous tumors of low malignant potential (Borderline tumors) -: Outcome-based study of 276 patients with long-term (≥ 5-year) follow-up
TA Longacre et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma
B Pothuri et al.
GYNECOLOGIC ONCOLOGY (2005)
Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study
A Gadducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment
V Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial
G Velikova et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Lymph node involvement in epithelial ovarian cancer:: Analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications
P Morice et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2003)
Prognostic factors for patients with advanced stage serous borderline tumours of the ovary
P Morice et al.
ANNALS OF ONCOLOGY (2003)
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
JB Trimbos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal P-32 or intravenous cyclophosphamide and cisplatin - A gynecologic oncology group study
RC Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Serous borderline tumors of the ovary - A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion
J Prat et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?
PM Flynn et al.
GYNECOLOGIC ONCOLOGY (2002)
Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary
S Camatte et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2002)
Mucinous tumors of the ovary -: A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas
IM Rodríguez et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
RE Bristow et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer
JMJ Piek et al.
JOURNAL OF PATHOLOGY (2001)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study
G Zanetta et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
I Vergote et al.
LANCET (2001)
Mucinous tumors of the ovary - A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'
KR Lee et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2000)
Ovarian micropapillary serous borderline tumors - Clinicopathologic features and outcome of seven surgically staged patients
NS Goldstein et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2000)
Borderline tumors of the ovary: Correlation of frozen and permanent histopathologic diagnosis
K Houck et al.
OBSTETRICS AND GYNECOLOGY (2000)
FDG PET evaluation of mucinous neoplasms: Correlation of FDG uptake with histopathologic features
KL Berger et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2000)
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
C Trope et al.
ANNALS OF ONCOLOGY (2000)
分享论文
